Can Molecular Breast Imaging With Tc-99m Sestamibi Safely Rule Out Malignancy in Pathologic Nipple Discharge?

Journal Article (2025)
Author(s)

Sofia C. Vaz (Champalimaud Clinical Center, Leiden University Medical Center)

Christinne L.S. Corion (Haaglanden Medical Center)

Jelle Goeman (Leiden University Medical Center)

Anneke M. Zeillemaker (Alrijne Hospital)

Rachel Hezemans (Alrijne Hospital)

Lioe Fee De Geus-Oei (Leiden University Medical Center, TU Delft - Applied Sciences, University of Twente)

Lenka M.Pereira Arias-Bouda (Leiden University Medical Center, Alrijne Hospital)

Department
RST/Radiation, Science and Technology
DOI related publication
https://doi.org/10.1097/RLU.0000000000005851 Final published version
More Info
expand_more
Publication Year
2025
Language
English
Department
RST/Radiation, Science and Technology
Journal title
Clinical Nuclear Medicine
Issue number
7
Volume number
50
Pages (from-to)
568-576
Downloads counter
196
Reuse Rights

Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.

Abstract

Purpose: Nipple discharge is the third most common breast-related complaint. It is recommended to exclude malignancy in pathologic nipple discharge (PND). Mammography and ultrasound are the first-line conventional diagnostic (CD) imaging. Although magnetic resonance is often used as a complementary modality, molecular breast imaging (MBI) with Tc-99m sestamibi may be a suitable alternative. Considering the lack of information on this subject and its clinical importance, this study aimed to evaluate the role of MBI in ruling out malignancy in patients with PND and negative/indeterminate CD. Patients and Methods: Retrospective cohort single-center study including all patients with PND evaluated by CD and MBI between 2012 and 2020. Pathology was considered the gold standard. Follow-up was used when pathology was not available. Results: Of the 96 cases of PND included, 78 were benign, and 18 (20%) corresponded to breast cancer (BC). Although CD and MBI were concordant in the BIRADS classification in 81% (78/96), half of BC were detected by MBI only. BC was located directly behind the nipple in a minority of patients (11%), meaning that MBI could significantly prevent futile central ductal excision. MBI presented higher sensitivity (83% vs. 33%) and negative predictive value (96% vs. 86%) than CD alone, with similar specificity (89% vs. 92%) and positive predictive value (63% vs. 50%). The area under the curve of MBI and CD was 0,86 (P-value<0.001 [95% CI: 0.75-0.97]) and 0.63 (P-value=0.091 [95% CI: 0.47-0.79]), respectively. Conclusions: MBI showed good diagnostic accuracy for detecting BC in patients with PND with negative/indeterminate findings on CD imaging.